查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2096711

神經病變疼痛治療​​市場—2026-2032年全球市場預測

Neuropathy Pain Treatment Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，神經病變疼痛治療​​市場將成長至 211.8 億美元，複合年成長率為 12.08%。

主要市場統計數據
基準年 2025 95.3億美元
預計年份：2026年 105.7億美元
預測年份：2032年 211.8億美元
複合年成長率 (%) 12.08%

由於糖尿病、癌症復健、自體免疫疾病、感染疾病、創傷性神經損傷和老化等因素導致周邊神經病變疼痛在全球日益加重，神經病變疼痛的治療變得至關重要。臨床上，神經病變疼痛的特徵是灼痛、刺痛、麻刺感、電擊樣感覺、異常性疼痛和痛覺過敏，通常由軀體感覺神經系統的損傷或功能障礙引起。治療通常包括藥物聯合治療，例如抗驚厥藥、抗憂鬱症、局部鎮痛藥和旨在最大限度減少鴉片類藥物使用的特定療法，以及介入治療、神經調控療法、物理治療、心理支持、血糖控制、營養管理和基礎疾病的治療。

糖尿病周邊神經病變、化療引起的周邊神經病變、帶狀皰疹後遺症神經痛、神經線病變、三叉神經痛以及與HIV、酒精攝取、維生素缺乏和慢性腎臟病相關的神經病變的診斷數量不斷增加，正在改變整體情況。由於持續性神經病變疼痛與睡眠障礙、運動功能下降、憂鬱症、焦慮、工作能力喪失以及醫療服務利用率增加有關，循證的多學科疼痛管理在醫療保健系統中變得日益重要。對於產業相關人員，主要機會在於實現持續鎮痛，同時減少副作用、多重用藥、鴉片類藥物暴露和治療中斷。儘管臨床指南和保險公司政策仍然優先考慮療效、安全性和功能性結果已得到證實的治療方法，但數位健康和​​人工智慧（AI）的應用正在實現對慢性神經病變疼痛的早期發現、治療最佳化和遠端監測。

神經病變疼痛治療​​的變革性變化

神經病變疼痛的治療方法正經歷著從以症狀為中心的治療方案轉向以機制為基礎的綜合治療方案的重大轉變。傳統上，神經病變疼痛的治療主要依賴口服藥物，且治療方案的選擇往往基於試驗。目前的實踐正朝著個別化治療方案的方向發展，這些方案會考慮疼痛表現型、合併症、腎功能和肝功能、精神健康狀況、藥物交互作用、虛弱程度以及患者報告的結果。這種轉變使得抗驚厥藥、 正腎上腺素再回收抑制劑（SNRIs）、三環抗憂鬱藥物、局部Lidocaine和辣椒素以及介入治療能夠得到更合理的應用。

人工智慧在治療神經病變疼痛的累積影響

人工智慧正透過改進檢測、分層、監測和支持治療決策，對神經病變疼痛的整體管理產生累積影響。在臨床實踐中，人工智慧驅動的分析可以透過分析電子健康記錄、實驗室數據、藥物組合模式、共病和患者自述症狀，幫助識別神經病變、疼痛性神經病變、藥物不耐受、跌倒、憂鬱症或用藥依從性差的高風險患者。這為早期介入和更積極主動的慢性疼痛管理創造了機會。

區域性神經病變疼痛治療​​的關鍵見解

由於糖尿病負擔日益加重、日本、中國和韓國等國人口老化速度加快以及城市地區專科醫療服務覆蓋範圍不斷擴大等因素，都市區在神經病變疼痛的治療方面至關重要。此外，該地區大都會圈在診斷和治療方面也存在顯著差異。儘管隨著糖尿病篩檢、腫瘤神經病變和復健計畫的推廣，人們對糖尿病和化療引起的周邊神經病變的認知不斷提高，但治療的廣泛應用仍然很大程度上受到成本效益和保險報銷制度差異的影響。

神經病變疼痛治療​​的主要團體分析

在東協，由於糖尿病、人口老化、癌症治療的擴展以及都市區文明病導致的代謝性疾病的增加等因素，神經性疼痛的負擔日益加重，導致對神經病變疼痛治療​​的需求不斷成長。區域優先事項包括加強基層醫療篩檢、減輕基本神經病變疼痛治療​​的經濟負擔、整合復健服務、擴大專科醫生診療網路。保險報銷制度、醫療基礎設施和遍遠地區醫療服務可近性的差異，導致成員國之間治療機會不均。

各國在神經病變疼痛治療​​的關鍵見解

在美國，已建立起一套高度發展的神經病變疼痛治療​​體系，這得益於大量的糖尿病患者、先進的疼痛管理基礎設施、癌症倖存者支持計畫以及健全的鴉片類藥物合理使用政策。在臨床實務中，非鴉片類藥物、外用藥物、行為療法、物理治療以及針對某些難治性病例的神經調控療法正日益受到重視。加拿大也採用類似的實證方法，並依託公共醫療保險覆蓋範圍和全國範圍內對慢性疼痛的關注，但各州和地區獲得多學科疼痛診所服務的機會可能有所不同。

為行業領導者提供的實用建議

產業領導者應優先考慮以實證醫學為基礎、盡可能減少鴉片類藥物使用的神經病變疼痛管理策略，這些策略應符合臨床指引和保險公司的期望。產品和服務組合必須涵蓋整個治療流程，包括早期篩檢、症狀評估、藥物治療、局部治療、數位監測、復健、行為療法以及針對難治性患者的介入措施。

調查方法

用於評估神經病變疼痛治療​​現況的調查方法是基於檢驗的二級研究、臨床證據綜述、監管分析以及對醫療保健趨勢的系統性解讀。所考慮的資訊來源包括同行評審的醫學文獻、臨床實踐指南、公共衛生出版刊物、監管文件、疾病負擔資料庫、藥物警戒資料以及與神經病變疼痛、糖尿病性神經神經病變、帶狀皰疹後遺症神經痛神經痛、化療引起的周圍神經病變和慢性疼痛管理相關的醫療保健政策參​​考資料。

結論

神經病變疼痛的治療正從一般的症狀管理轉向更安全、更個人化、多學科的綜合治療。糖尿病和癌症倖存者負擔加重、人們對慢性神經痛的認知不斷提高、鴉片類藥物管制更加嚴格、神經調控療法取得進展以及人工智慧輔助評估和遠端監測的出現，都在推動這一領域的變革。無論身處何地，最迫切的挑戰都包括早期診斷、提高循證治療的可及性、加強患者教育以及提高長期治療依從性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：神經病變疼痛治療​​市場：依治療類型分類

  • 輔助療法
    • 草藥補充劑
    • 身心療法
  • 醫療設備
    • 神經調控
    • TENS
  • 製藥
    • 止痛藥
      • 非鴉片類藥物
      • 鴉片類藥物
    • 抗驚厥藥物
    • 抗憂鬱症
    • 外用製劑
      • 辣椒素
      • Lidocaine
  • 治療方法
    • 針刺
    • 按摩療法
    • 物理治療

第8章：神經病變疼痛治療​​市場：依給藥途徑分類

  • 注射藥物
    • 靜脈
    • 皮下
  • 口服
    • 膠囊
    • 藥片
  • 外用
    • 奶油
    • 凝膠
  • 經皮給藥

第9章：神經病變疼痛治療​​市場：依適應症分類

  • 中樞神經神經病變疼痛
    • 脊髓損傷引起的疼痛
    • 中風後神經病變疼痛
  • 周邊神經病變疼痛

第10章：神經病變疼痛治療​​市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專科診所

第11章：神經病變疼痛治療​​市場：依最終用戶分類

  • 門診治療
  • 診所
  • 居家醫療
  • 醫院

第12章：神經病變疼痛治療​​市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：神經病變疼痛治療​​市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：神經病變疼痛治療​​市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Baxter International Inc.
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Bristol Myers Squibb Company
  • DAIICHI SANKYO COMPANY, LIMITED
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo International PLC
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Johnson and Johnson Services, Inc.
  • Medtronic PLC
  • NeuroMetrix, Inc.
  • Nevro Corporation
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
Product Code: MRR-957C47F9180B

The Neuropathy Pain Treatment Market is projected to grow by USD 21.18 billion at a CAGR of 12.08% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.53 billion
Estimated Year [2026] USD 10.57 billion
Forecast Year [2032] USD 21.18 billion
CAGR (%) 12.08%

Neuropathy pain treatment is gaining strategic importance as diabetes, cancer survivorship, autoimmune disorders, infections, traumatic nerve injury, and aging populations increase the global burden of peripheral neuropathic pain. Clinically, neuropathic pain is characterized by burning, shooting, tingling, electric-shock sensations, allodynia, and hyperalgesia, often resulting from damage or dysfunction in the somatosensory nervous system. Treatment pathways commonly combine pharmacologic therapies such as anticonvulsants, antidepressants, topical analgesics, and selected opioid-sparing approaches with interventional procedures, neuromodulation, physical rehabilitation, psychological support, glycemic control, nutritional correction, and management of underlying disease causes.

The treatment landscape is being shaped by rising diagnosis of diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, postherpetic neuralgia, radiculopathy, trigeminal neuralgia, and neuropathy linked to HIV, alcohol use, vitamin deficiencies, and chronic kidney disease. Health systems are increasingly emphasizing evidence-based, multidisciplinary pain management because persistent neuropathic pain is associated with sleep disruption, reduced mobility, depression, anxiety, work impairment, and higher healthcare utilization. For industry stakeholders, the central opportunity lies in improving durable pain relief while reducing adverse effects, polypharmacy, opioid exposure, and treatment discontinuation. Clinical guidelines and payer policies continue to favor therapies with proven efficacy, safety, and functional outcomes, while digital health and artificial intelligence are beginning to support earlier identification, treatment optimization, and remote monitoring of chronic neuropathic pain.

Transformative Shifts in the Neuropathy Pain Treatment Landscape

The neuropathy pain treatment landscape is undergoing a major transition from symptom-focused prescribing toward integrated, mechanism-informed care. Historically, neuropathic pain management relied heavily on oral medications, with treatment selection often based on trial-and-error. Current practice is shifting toward individualized regimens that consider pain phenotype, comorbidities, renal and hepatic function, mental health status, drug interactions, frailty, and patient-reported outcomes. This transformation supports more precise use of anticonvulsants, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, topical lidocaine or capsaicin, and interventional options.

A second shift is the growing priority of opioid stewardship. Public health authorities and clinical societies have highlighted the limited long-term role of opioids in many chronic non-cancer pain conditions and the risks of dependence, overdose, constipation, cognitive impairment, and falls. As a result, healthcare providers are expanding non-opioid neuropathic pain therapies, multimodal rehabilitation, behavioral pain strategies, and device-based approaches such as spinal cord stimulation and peripheral nerve stimulation for selected refractory cases.

A third transformation is occurring through earlier screening and prevention. Diabetes care models increasingly include foot examinations, neuropathy screening, glycemic management, cardiovascular risk reduction, and patient education to reduce complications such as ulcers and amputations. Oncology programs are also placing greater attention on chemotherapy-induced peripheral neuropathy, dose modification, survivorship care, and symptom monitoring. Together, these shifts are moving the industry toward longitudinal nerve pain management that prioritizes function, safety, adherence, and quality of life.

Cumulative Impact of Artificial Intelligence on Neuropathy Pain Treatment

Artificial intelligence is becoming a cumulative force across neuropathy pain treatment by improving detection, stratification, monitoring, and therapeutic decision support. In clinical settings, AI-enabled analytics can support identification of patients at higher risk for diabetic neuropathy, painful neuropathy, medication intolerance, falls, depression, or poor adherence by analyzing electronic health records, laboratory data, prescription patterns, comorbidities, and patient-reported symptoms. This creates opportunities for earlier intervention and more proactive chronic pain management.

AI is also strengthening neuropathic pain assessment. Machine learning models applied to quantitative sensory testing, wearable sensor data, gait analysis, sleep metrics, and digital pain diaries can help capture pain variability and functional impact beyond episodic clinic visits. Natural language processing can extract neuropathy-related symptoms from clinical notes, oncology records, and primary care documentation, supporting better recognition of underdiagnosed conditions such as chemotherapy-induced peripheral neuropathy and painful diabetic neuropathy.

In therapeutic development and care delivery, AI can accelerate target discovery, optimize clinical trial recruitment, identify responder subgroups, and support personalized treatment pathways. However, responsible implementation requires validated algorithms, representative datasets, clinician oversight, transparent performance reporting, cybersecurity safeguards, and compliance with medical device, data protection, and health equity requirements. The most meaningful impact will come from AI tools that reduce diagnostic delays, improve medication selection, flag safety risks, and enhance remote management without replacing clinical judgment.

Key Regional Insights for Neuropathy Pain Treatment

Asia-Pacific is a critical region for neuropathy pain treatment due to the high and rising burden of diabetes, rapid population aging in countries such as Japan, China, and South Korea, and expanding access to specialty care in urban centers. The region also faces substantial variation in diagnosis and treatment access between metropolitan and rural settings. Growing use of diabetes screening, oncology services, and rehabilitation programs is increasing recognition of diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy, while affordability and reimbursement differences continue to shape therapy uptake.

North America demonstrates advanced adoption of multidisciplinary pain management, neuromodulation, telehealth, and opioid-sparing care pathways. The United States and Canada have extensive clinical infrastructure for diabetes management, oncology survivorship, pain medicine, podiatry, and rehabilitation, supporting broader identification of neuropathic pain. Regulatory focus on opioid risk mitigation and evidence-based prescribing continues to influence treatment patterns, increasing demand for non-opioid pharmacologic therapies, topical treatments, behavioral care, and device-based interventions for refractory pain.

Latin America is characterized by rising diabetes prevalence, expanding private healthcare access, and growing awareness of chronic nerve pain among primary care and specialist providers. Brazil and Mexico are central to regional demand due to their large patient populations and evolving chronic disease programs. However, disparities in healthcare access, specialist availability, and reimbursement can limit timely diagnosis and continuity of neuropathy pain treatment, especially outside major cities.

Europe benefits from strong clinical guideline adoption, broad-based healthcare coverage in many countries, and established pain, neurology, endocrinology, and oncology care networks. The region emphasizes evidence-based use of neuropathic pain medications, rehabilitation, and careful opioid governance. Western European countries often lead in structured pain pathways and digital health integration, while parts of Eastern Europe continue to improve access to specialist diagnostics and advanced interventions.

The Middle East is experiencing growing demand for neuropathy pain treatment due to high diabetes prevalence in several countries, increasing obesity-related metabolic disease, and expanding tertiary healthcare infrastructure. Gulf countries are investing in specialty clinics, digital health, and chronic disease management, supporting earlier recognition of diabetic neuropathy and related complications. Access remains uneven across the broader region, with affordability, workforce distribution, and conflict-related health system disruption affecting care continuity.

Africa faces a dual challenge of increasing noncommunicable diseases and persistent resource constraints. Diabetes-related neuropathy, HIV-associated neuropathy, nutritional deficiencies, infectious disease complications, and treatment-related neuropathies contribute to regional disease burden. Diagnosis is often delayed due to limited specialist access, constrained pain management resources, and uneven availability of essential medicines. Strengthening primary care screening, affordable treatment access, diabetes control, and community-level education is central to improving outcomes across the continent.

Key Group Insights for Neuropathy Pain Treatment

ASEAN countries are seeing growing demand for neuropathy pain treatment as diabetes, aging, cancer care expansion, and urban lifestyle-related metabolic disorders increase the burden of nerve pain. Regional priorities include strengthening primary care screening, improving affordability of essential neuropathic pain medicines, integrating rehabilitation, and expanding specialist referral networks. Differences in reimbursement, healthcare infrastructure, and rural access create varied treatment adoption across member states.

The GCC represents a high-priority group due to elevated rates of diabetes and obesity, strong investment in healthcare modernization, and expanding digital health capabilities. Chronic disease management programs, endocrinology services, and tertiary care centers are central to improving diagnosis of diabetic peripheral neuropathy. The GCC's policy focus on preventive care and health system digitization supports adoption of remote monitoring, patient education, and integrated pain care.

The European Union benefits from harmonized regulatory standards, strong pharmacovigilance frameworks, and broad use of clinical guidelines for neuropathic pain. EU health systems increasingly emphasize opioid stewardship, health technology assessment, patient-reported outcomes, and equitable access to evidence-based therapies. Cross-border research collaboration and digital health regulation are supporting more structured approaches to chronic pain care and real-world evidence generation.

BRICS countries collectively represent a large and diverse neuropathy pain treatment environment shaped by substantial diabetes burden, expanding hospital networks, and uneven access to specialist pain services. China, India, Brazil, Russia, and South Africa each face distinct challenges related to affordability, primary care capacity, and regional disparities. Their scale makes prevention, early screening, and low-cost evidence-based treatment pathways particularly important.

The G7 countries generally have mature healthcare systems, established clinical guidelines, advanced pain medicine capabilities, and growing adoption of digital health tools. Aging populations, diabetes, cancer survivorship, and chronic pain policy reforms are key drivers of neuropathy pain treatment demand. These countries are also more likely to integrate real-world evidence, pharmacovigilance, and patient-centered outcomes into decision-making.

NATO member countries overlap significantly with advanced healthcare systems in North America and Europe, where chronic pain management, rehabilitation, military medicine, and trauma-related neuropathy are relevant considerations. Service-related nerve injuries, musculoskeletal trauma, and post-surgical neuropathic pain contribute to treatment needs, while coordinated medical standards and rehabilitation systems support structured approaches to functional recovery and long-term pain management.

Key Country Insights for Neuropathy Pain Treatment

The United States has a highly developed neuropathy pain treatment ecosystem shaped by a large diabetes population, advanced pain medicine infrastructure, oncology survivorship programs, and strong opioid stewardship policies. Clinical practice increasingly favors non-opioid medications, topical agents, behavioral interventions, physical therapy, and neuromodulation for selected refractory cases. Canada follows similar evidence-based approaches, supported by public healthcare coverage and national attention to chronic pain, though access to multidisciplinary pain clinics can vary by province and geography.

Mexico and Brazil are central Latin American countries for neuropathy pain treatment because of their large populations and growing burden of diabetes and metabolic disease. Mexico faces increasing demand for diabetic neuropathy screening and treatment across public and private systems, while Brazil benefits from expanding specialty care in major cities and broad public health infrastructure. In both countries, access gaps, affordability, and specialist availability influence timely diagnosis and treatment adherence.

The United Kingdom emphasizes guideline-based neuropathic pain management within a structured healthcare system, with strong focus on medication review, functional outcomes, and opioid risk reduction. Germany has advanced pain medicine, neurology, diabetes care, and rehabilitation services, supporting multidisciplinary treatment pathways. France maintains strong specialist care and pharmacovigilance systems, while Italy and Spain combine aging populations, high chronic disease needs, and established public health systems that support broad access to neuropathic pain treatment. Russia has significant demand related to diabetes, aging, and neurological disorders, with treatment access varying across regions and between urban and rural healthcare settings.

China faces a major neuropathy pain treatment challenge due to its large diabetes population, aging demographics, and expanding oncology services. Urban hospitals increasingly provide advanced diagnostics and pain care, while primary care capacity building remains important for early detection. India has rising diabetes prevalence and a large need for affordable peripheral neuropathy treatment, with opportunities centered on screening, generic medicines, telemedicine, and clinician education. Japan's super-aged population and mature healthcare system drive demand for safe, tolerable nerve pain therapies, fall-risk reduction, and integrated geriatric pain management. Australia has strong clinical governance and chronic disease programs, with attention to rural access and telehealth-enabled pain care. South Korea combines advanced healthcare infrastructure, digital health adoption, and growing diabetes and oncology survivorship needs, supporting increased recognition and treatment of neuropathic pain.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-based, opioid-sparing neuropathy pain treatment strategies that align with clinical guidelines and payer expectations. Product and service portfolios should address the full continuum of care, including early screening, symptom assessment, pharmacologic therapy, topical treatment, digital monitoring, rehabilitation, behavioral health, and interventional care for refractory patients.

A key recommendation is to invest in patient stratification. Neuropathic pain is heterogeneous, and treatment response varies by etiology, pain phenotype, comorbidities, age, concomitant medications, and psychosocial factors. Healthcare organizations should support validated assessment tools, patient-reported outcome measures, and real-world evidence programs that clarify which patients benefit from specific interventions.

Stakeholders should also strengthen clinician education in primary care, endocrinology, oncology, neurology, podiatry, and pain medicine. Earlier diagnosis of diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, and postherpetic neuralgia can reduce complications and improve quality of life. Educational initiatives should emphasize safe prescribing, titration, adverse-effect management, medication adherence, foot care, and referral criteria.

Digital health and AI initiatives should be pursued cautiously but proactively. Remote pain diaries, wearable-enabled functional monitoring, telehealth follow-up, and AI-supported risk identification can improve continuity of care, particularly for chronic neuropathy patients who require long-term monitoring. Solutions must be clinically validated, interoperable, privacy-compliant, and designed to reduce, not increase, workflow burden.

Finally, industry leaders should tailor access strategies to regional realities. High-income settings may prioritize advanced neuromodulation, digital therapeutics, and integrated multidisciplinary care, while emerging settings require affordable medicines, primary care screening, simplified treatment protocols, and scalable education programs. Across all settings, success depends on demonstrating improved pain relief, function, safety, adherence, and patient quality of life.

Research Methodology

The research methodology for assessing the neuropathy pain treatment landscape is grounded in verified secondary research, clinical evidence review, regulatory analysis, and structured interpretation of healthcare trends. Sources considered include peer-reviewed medical literature, clinical practice guidelines, public health agency publications, regulatory documents, disease burden databases, pharmacovigilance resources, and healthcare policy references relevant to neuropathic pain, diabetic neuropathy, postherpetic neuralgia, chemotherapy-induced peripheral neuropathy, and chronic pain management.

The methodology evaluates treatment modalities across pharmacologic, topical, interventional, device-based, rehabilitative, behavioral, and digital care categories. Evidence is assessed based on clinical relevance, safety profile, guideline support, patient outcomes, real-world applicability, and regional healthcare access considerations. Particular attention is given to opioid stewardship, non-opioid pain management, patient-reported outcomes, comorbidity management, and multidisciplinary care pathways.

Regional, group, and country insights are developed by synthesizing publicly available indicators related to diabetes burden, aging demographics, oncology survivorship, healthcare infrastructure, reimbursement environment, regulatory maturity, digital health adoption, and specialist access. The analysis avoids unsupported assumptions and excludes market sizing, market share, and forecasting. Findings are structured to support strategic decision-making for stakeholders involved in neuropathy pain treatment, chronic pain care, medical technology, digital health, and healthcare delivery.

Conclusion

Neuropathy pain treatment is evolving from generalized symptom control toward safer, more personalized, and multidisciplinary care. The field is being reshaped by the growing burden of diabetes and cancer survivorship, greater recognition of chronic nerve pain, stricter opioid stewardship, advances in neuromodulation, and the emergence of AI-enabled assessment and remote monitoring. Across regions, the most urgent needs include earlier diagnosis, broader access to evidence-based therapies, better patient education, and improved long-term treatment adherence.

High-income healthcare systems are advancing integrated pain pathways, digital health tools, and specialty interventions, while emerging healthcare systems are focused on affordable access, primary care capacity, and scalable screening programs. Regional and country-level differences in reimbursement, infrastructure, clinical workforce, and chronic disease management will continue to shape adoption patterns.

For industry leaders, the strongest strategic direction is clear: deliver clinically validated neuropathy pain solutions that improve pain relief, function, safety, and quality of life while reducing treatment burden and avoidable complications. Organizations that combine evidence-based therapy, patient-centered care, responsible AI, and access-focused implementation will be best positioned to address the expanding global need for effective neuropathic pain management.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Neuropathy Pain Treatment Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Complementary
    • 7.2.1. Herbal Supplements
    • 7.2.2. Mind Body Techniques
  • 7.3. Device
    • 7.3.1. Neuromodulation
    • 7.3.2. TENS
  • 7.4. Drug
    • 7.4.1. Analgesics
      • 7.4.1.1. Non-Opioids
      • 7.4.1.2. Opioids
    • 7.4.2. Anticonvulsants
    • 7.4.3. Antidepressants
    • 7.4.4. Topical Agents
      • 7.4.4.1. Capsaicin
      • 7.4.4.2. Lidocaine
  • 7.5. Therapy
    • 7.5.1. Acupuncture
    • 7.5.2. Massage Therapy
    • 7.5.3. Physical Therapy

8. Neuropathy Pain Treatment Market, by Route Of Administration

  • 8.1. Introduction
  • 8.2. Injectable
    • 8.2.1. Intravenous
    • 8.2.2. Subcutaneous
  • 8.3. Oral
    • 8.3.1. Capsules
    • 8.3.2. Tablets
  • 8.4. Topical
    • 8.4.1. Creams
    • 8.4.2. Gels
  • 8.5. Transdermal

9. Neuropathy Pain Treatment Market, by Indication

  • 9.1. Introduction
  • 9.2. Central Neuropathic Pain
    • 9.2.1. Spinal Cord Injury Pain
    • 9.2.2. Post-Stroke Neuropathic Pain
  • 9.3. Peripheral Neuropathy

10. Neuropathy Pain Treatment Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacy
  • 10.3. Online Pharmacy
  • 10.4. Retail Pharmacy
  • 10.5. Specialty Clinic

11. Neuropathy Pain Treatment Market, by End User

  • 11.1. Introduction
  • 11.2. Ambulatory Care
  • 11.3. Clinic
  • 11.4. Home Care
  • 11.5. Hospital

12. Neuropathy Pain Treatment Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Neuropathy Pain Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Neuropathy Pain Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. AbbVie Inc.
  • 16.3. Amgen Inc.
  • 16.4. Astellas Pharma Inc.
  • 16.5. AstraZeneca PLC
  • 16.6. Aurobindo Pharma Limited
  • 16.7. Baxter International Inc.
  • 16.8. Bayer AG
  • 16.9. Biogen Inc.
  • 16.10. Boehringer Ingelheim International GmbH
  • 16.11. Boston Scientific Corporation
  • 16.12. Bristol Myers Squibb Company
  • 16.13. DAIICHI SANKYO COMPANY, LIMITED
  • 16.14. Dr. Reddy's Laboratories Ltd.
  • 16.15. Eli Lilly and Company
  • 16.16. Endo International PLC
  • 16.17. GlaxoSmithKline PLC
  • 16.18. H. Lundbeck A/S
  • 16.19. Johnson and Johnson Services, Inc.
  • 16.20. Medtronic PLC
  • 16.21. NeuroMetrix, Inc.
  • 16.22. Nevro Corporation
  • 16.23. Novartis AG
  • 16.24. Pfizer Inc.
  • 16.25. Sun Pharmaceutical Industries Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROPATHY PAIN TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL NEUROPATHY PAIN TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL NEUROPATHY PAIN TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL NEUROPATHY PAIN TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL NEUROPATHY PAIN TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMPLEMENTARY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPLEMENTARY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMPLEMENTARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HERBAL SUPPLEMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HERBAL SUPPLEMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HERBAL SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MIND BODY TECHNIQUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MIND BODY TECHNIQUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MIND BODY TECHNIQUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROMODULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANALGESICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANALGESICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NON-OPIOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON-OPIOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NON-OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OPIOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OPIOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TOPICAL AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TOPICAL AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TOPICAL AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CAPSAICIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CAPSAICIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CAPSAICIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LIDOCAINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LIDOCAINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LIDOCAINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ACUPUNCTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ACUPUNCTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ACUPUNCTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MASSAGE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MASSAGE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MASSAGE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PHYSICAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PHYSICAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PHYSICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CREAMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CREAMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CREAMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CENTRAL NEUROPATHIC PAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CENTRAL NEUROPATHIC PAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CENTRAL NEUROPATHIC PAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SPINAL CORD INJURY PAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL SPINAL CORD INJURY PAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SPINAL CORD INJURY PAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL POST-STROKE NEUROPATHIC PAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL POST-STROKE NEUROPATHIC PAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL POST-STROKE NEUROPATHIC PAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PERIPHERAL NEUROPATHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PERIPHERAL NEUROPATHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PERIPHERAL NEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL SPECIALTY CLINIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL SPECIALTY CLINIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL SPECIALTY CLINIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL AMBULATORY CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL AMBULATORY CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL AMBULATORY CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CLINIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CLINIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CLINIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CENTRAL NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CENTRAL NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CENTRAL NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CENTRAL NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CENTRAL NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CENTRAL NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CENTRAL NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 248. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 249. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 250. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 251. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 252. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 253. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 254. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 255. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 256. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 257. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 258. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CENTRAL NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 259. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CENTRAL NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CENTRAL NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. G7 NEUROPATHY PAIN TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 294. G7 NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. G7 NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 296. G7 NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 297. G7 NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 298. G7 NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 299. G7 NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 300. G7 NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 301. G7 NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 302. G7 NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 303. G7 NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 304. G7 NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 305. G7 NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 306. G7 NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CENTRAL NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 307. G7 NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 308. G7 NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. NATO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 310. NATO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. NATO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 312. NATO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 313. NATO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 314. NATO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 315. NATO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 316. NATO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 317. NATO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 318. NATO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 319. NATO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 320. NATO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 321. NATO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 322. NATO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CENTRAL NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 323. NATO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 324. NATO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 325. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 333. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 334. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 335. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 336. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 337. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 338. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 339. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CENTRAL NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 340. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 341. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 342. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 343. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 344. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 345. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 346. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 347. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 348. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 349. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 350. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 351. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 352. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 353. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 354. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 355. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CENTRAL NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 356. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 357. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (